Pyrotinib monotherapy for advanced HER2-positive esophageal adenocarcinoma with trastuzumab resistance and chemotherapy intolerance: a case report and literature review

Abstract HER2-positive advanced esophageal adenocarcinoma (EAC) cases demonstrate a poor prognosis because of drug resistance that develops after standard first-line trastuzumab therapy. The patient was initially diagnosed with stage cT2N1M0 III EAC. He underwent neoadjuvant chemotherapy, radical es...

Full description

Bibliographic Details

Published in:	Discover Oncology
Main Authors:	Tao Wang, Mingyuan He, Wei Guan
Format:	Article
Language:	English
Published:	Springer 2025-03-01
Subjects:	Esophageal adenocarcinoma HER2 Pyrotinib Trastuzumab Cadonilimab Drug resistance
Online Access:	https://doi.org/10.1007/s12672-025-02049-6